Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Novo Nordisk A/S
Novo Nordisk: New study directly comparing insulin delivery devices shows that Next Generation FlexPen® has a significantly lower injection force than SoloStar® and KwikPen®
June 15th, 2009
New data published this week in Expert Opinion Pharmacotherapy has revealed that Next Generation FlexPen®, Novo Nordisk’s prefilled insulin delivery device, has a significantly lower injection force than two other devices, SoloStar® and KwikPen®.1,2,3 Previous studies show that people with diabetes prefer a lower injection force.4,5 The study revealed that the injection (dose) force of Next Generation FlexPen® was 12–25% lower than SoloStar® and 35–41% lower than KwikPen®.1 In addition to the reduced injection force, this study and others have shown that Next Generation FlexPen® has advantages over SoloStar® and KwikPen® in providing improved accuracy.1,6,7 “Patients with diabetes...
Source: Diabetes Week (2009-06-15)
|
